secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001558370-24-010960
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Q2 net revenue $172.8M (+29% YoY); non-GAAP EPS $1.05 vs $0.76; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Net product revenue $172.8M for Q2 2024, up 29% from $134.2M in Q2 2023.
- GAAP net income $11.6M ($0.20 diluted EPS) vs $34.3M ($0.56) prior year; non-GAAP adjusted net income $60.6M ($1.05 diluted EPS) vs $45.9M ($0.76).
- Average patients on WAKIX increased sequentially by ~250 to approximately 6,550 for the quarter.
- FY 2024 net product revenue guidance reiterated at $700-$720 million.
- FDA approved WAKIX for pediatric narcolepsy (EDS) on June 21, 2024; commercial launch began July 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024010960/0001558370-24-010960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024010960/hrmy-20240806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer